文献速递产科母胎医学

眼动脉多普勒联合其他生物标志物预测35-37周妊娠子痫前期

Ophthalmic artery Doppler in combination with other biomarkers in prediction of pre-eclampsia at 35-37 weeks' gestation.
PubMed 文献 · Ultrasound Obstet Gynecol · 2021-03-15

这项前瞻性观察研究纳入2287例妊娠,在35+0至36+6周评估母体眼动脉多普勒(PSV比值)联合MAP、UtA-PI、PlGF和sFlt-1预测子痫前期。PSV比值可提高各模型预测性能,尤其对评估后3周内分娩的子痫前期,假阳性率10%时检出率从31.0%提升至69.4%(母体因素模型)。结论认为眼动脉多普勒有潜力改善晚孕期子痫前期筛查,但需进一步验证。

要点

  • 眼动脉PSV比值可提升子痫前期筛查检出率,尤其对3周内分娩者。
  • 联合母体因素和MAP时,3周内分娩子痫前期检出率从74.1%升至83.4%。
  • 联合母体因素、MAP和PlGF时,3周内分娩子痫前期检出率达88.6%。

核心结论

  • 眼动脉多普勒有潜力改善35-37周子痫前期筛查性能,尤其是评估后3周内分娩的临近子痫前期,但需进一步研究验证。

研究设计与样本

  • 前瞻性观察研究,纳入2287例在35+0至36+6周进行常规产检的妊娠妇女。
  • 采用竞争风险模型结合母体因素、病史和生物标志物估计个体化风险。

主要发现

  • 研究人群中有60例(2.6%)发生子痫前期,其中19例(0.8%)在评估后3周内分娩。
  • 假阳性率10%时,PSV比值使母体因素模型对任何阶段分娩子痫前期的检出率从25.4%升至50.6%。
  • 假阳性率10%时,PSV比值使母体因素模型对3周内分娩子痫前期的检出率从31.0%升至69.4%。
  • 联合母体因素、MAP和PSV比值对任何阶段妊娠期高血压的检出率为59.4%(95%CI 58.6-82.5%)。
  • 联合母体因素、MAP和PSV比值对3周内分娩妊娠期高血压的检出率为86.7%(95%CI 82.4-100%)。

关键数值与推荐

  • 假阳性率10%时,母体因素+MAP+PlGF+sFlt-1模型加PSV比值对任何阶段子痫前期检出率从75.7%升至76.7%。
  • 假阳性率10%时,母体因素+MAP+UtA-PI模型加PSV比值对3周内分娩子痫前期检出率从77.1%升至85.0%。

临床怎么用

  • 在35-37周筛查中,可考虑将眼动脉多普勒PSV比值加入现有生物标志物模型以提升子痫前期预测,尤其针对3周内分娩风险。
  • 目前证据尚需外部验证,不宜单独作为临床决策依据。

局限性

  • 研究为观察性设计,需进一步研究验证眼动脉多普勒的筛查价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the potential value of maternal ophthalmic artery Doppler at 35-37 weeks' gestation in combination with the established biomarkers of pre-eclampsia (PE), including mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI), serum placental growth factor (PlGF) and serum soluble fms-like tyrosine kinase-1 (sFlt-1), in the prediction of subsequent development of PE. METHODS: This was a prospective observational study in women attending for a routine hospital visit at 35 + 0 to 36 + 6 weeks' gestation. This visit included recording of maternal demographic characteristics and medical history, ultrasound examination for fetal anatomy and growth, assessment of flow velocity waveforms from the maternal ophthalmic arteries, and measurement of MAP, UtA-PI, serum PlGF and serum sFlt-1. The competing-risks model was used to estimate the individual patient-specific risks of delivery with PE at any time and at < 3 weeks after assessment by a combination of maternal demographic characteristics and medical history with biomarkers. The area under the receiver-operating-characteristics curve and detection rate (DR) of delivery with PE, at a 10% false-positive rate (FPR), in screening by combinations of maternal factors with ophthalmic artery second to first peak of systolic velocity ratio (PSV ratio), MAP, UtA-PI, serum PlGF and serum sFlt-1 were determined. The modeled performance of screening for PE was also estimated. RESULTS: The study population of 2287 pregnancies contained 60 (2.6%) that developed PE, including 19 (0.8%) that delivered with PE at < 3 weeks after assessment. The PSV ratio improved the prediction of PE with delivery at any stage after assessment provided by maternal factors alone (from 25.4% to 50.6%), maternal factors and MAP (54.3% to 62.7%), maternal factors, MAP and PlGF (68.3% to 70.8%) and maternal factors, MAP, PlGF and sFlt-1 (75.7% to 76.7%), at a FPR of 10%. The PSV ratio also improved the prediction of PE with delivery at < 3 weeks after assessment provided by maternal factors alone (from 31.0% to 69.4%), maternal factors and MAP (74.1% to 83.4%), maternal factors, MAP and UtA-PI (77.1% to 85.0%) and maternal factors, MAP and PlGF (84.8% to 88.6%). The empirical results for DR at a 10% FPR were consistent with the modeled results. Screening by a combination of maternal factors with MAP and PSV ratio also detected 59.4% (95% CI, 58.6-82.5%) of cases of gestational hypertension with delivery at any stage after assessment, and 86.7% (95% CI, 82.4-100%) of those with delivery at < 3 weeks after assessment. CONCLUSION: Ophthalmic artery Doppler could potentially improve the performance of screening for PE at 35-37 weeks, especially imminent PE with delivery within 3 weeks after assessment, but further studies are needed to validate this finding. © 2020 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Sarno M, Wright A, Vieira N, et al. Ophthalmic artery Doppler in combination with other biomarkers in prediction of pre-eclampsia at 35-37 weeks' gestation. Ultrasound Obstet Gynecol. 2021. PMID: 33073902. doi:10.1002/uog.23517

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。